Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.
Feature|Articles|August 20, 2026
How to Rebuild Pharma Operating Model for an AI Era
In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI surfaces is.
Advertisement
Advertisement
In the early 2000s, AstraZeneca’s gefitinib program in lung cancer was widely viewed as disappointing based on overall trial results. Yet buried within the data was a striking signal: a subgroup of patients experienced dramatic tumor responses—patients later shown to carry EGFR mutations. The finding became a landmark in biomarker-driven oncology, proving that the right therapy can look ineffective in the average patient while being transformative for the right subgroup.
Related to this article
Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.
While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Clinical data harmonization is the real bottleneck standing between life sciences companies and AI's transformative potential.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Advertisement
Advertisement